Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Novel anti-inflammatory therapy for Parkinson's disease.

Gao HM, Liu B, Zhang W, Hong JS.

Trends Pharmacol Sci. 2003 Aug;24(8):395-401. Review.

PMID:
12915048
2.

Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.

Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R.

Curr Pharm Des. 2007;13(18):1925-8. Review.

PMID:
17584117
3.

Novel anti-inflammatory and neuroprotective agents for Parkinson's disease.

Lu L, Li F, Wang X.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):232-40. Review.

PMID:
20015029
5.
6.

3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.

Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Zhang W, Kim HC, Hong JS.

FASEB J. 2005 Mar;19(3):395-7. Epub 2004 Dec 13.

7.

Neurodegeneration and inflammation in Parkinson's disease.

Phani S, Loike JD, Przedborski S.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S207-9. doi: 10.1016/S1353-8020(11)70064-5. Review.

PMID:
22166436
8.

Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.

Whitton PS.

Curr Opin Investig Drugs. 2010 Jul;11(7):788-94. Review.

PMID:
20571974
9.
10.

Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?

Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE, Ruhn KA, Tran TA.

Front Biosci. 2008 Jan 1;13:709-17. Review.

PMID:
17981581
11.

Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.

Thakur P, Nehru B.

Neuroscience. 2013 Feb 12;231:420-31. doi: 10.1016/j.neuroscience.2012.11.006. Epub 2012 Nov 14.

PMID:
23159314
12.

Inflammation in Parkinson's disease.

Tufekci KU, Meuwissen R, Genc S, Genc K.

Adv Protein Chem Struct Biol. 2012;88:69-132. doi: 10.1016/B978-0-12-398314-5.00004-0. Review.

PMID:
22814707
13.
14.

Non-steroidal anti-inflammatory drugs in Parkinson's disease.

Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G.

Exp Neurol. 2007 Jun;205(2):295-312. Epub 2007 Feb 23. Review.

PMID:
17433296
15.

Neuroinflammation in Parkinson's disease.

Hirsch EC, Vyas S, Hunot S.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2. doi: 10.1016/S1353-8020(11)70065-7. Review.

PMID:
22166438
16.

Inflammation as a causative factor in the aetiology of Parkinson's disease.

Whitton PS.

Br J Pharmacol. 2007 Apr;150(8):963-76. Epub 2007 Mar 5. Review.

17.

Inflammation and Parkinson's disease.

Wersinger C, Sidhu A.

Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):221-42. Review.

PMID:
14561187
18.

Neuroprotective strategies in Parkinson's disease : an update on progress.

Mandel S, Grünblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB.

CNS Drugs. 2003;17(10):729-62. Review.

PMID:
12873156
19.

Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.

Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybyłkowski A, Członkowski A, Członkowska A.

Int Immunopharmacol. 2004 Oct;4(10-11):1307-18.

PMID:
15313429
20.

Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?

Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A.

Int Rev Neurobiol. 2007;82:235-46. Review.

PMID:
17678964
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk